Safety Evaluations of Nivolumab (Anti-PD-1) Added To Chemotherapy (CRT) Platforms In Patients With Intermediate And High-Risk Local-Regionally Advanced Head and Neck Squamous Cell Carcinoma
Phase of Trial: Phase III
Latest Information Update: 18 Jul 2017
At a glance
- Drugs Nivolumab (Primary) ; Cetuximab; Cisplatin
- Indications Head and neck cancer; Squamous cell cancer
- Focus Adverse reactions; Therapeutic Use
- 06 Jun 2017 Trial design presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
- 19 Sep 2016 Status changed from not yet recruiting to recruiting.
- 16 Jun 2016 Planned initiation date changed from 1 May 2016 to 1 Jun 2016.